- Home
- EXP vs ROIV Comparison
EXP vs ROIV Comparison
Compare EXP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXP
- ROIV
- Stock Information
- Founded
- EXP 1963
- ROIV 2014
- Country
- EXP United States
- ROIV United Kingdom
- Employees
- EXP N/A
- ROIV N/A
- Industry
- EXP Building Materials
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- EXP Industrials
- ROIV Health Care
- Exchange
- EXP Nasdaq
- ROIV Nasdaq
- Market Cap
- EXP 7.3B
- ROIV 8.4B
- IPO Year
- EXP 1994
- ROIV N/A
- Fundamental
- Price
- EXP $240.02
- ROIV $10.79
- Analyst Decision
- EXP Buy
- ROIV Buy
- Analyst Count
- EXP 11
- ROIV 4
- Target Price
- EXP $275.45
- ROIV $17.50
- AVG Volume (30 Days)
- EXP 278.7K
- ROIV 5.9M
- Earning Date
- EXP 05-20-2025
- ROIV 05-29-2025
- Dividend Yield
- EXP 0.42%
- ROIV N/A
- EPS Growth
- EXP N/A
- ROIV N/A
- EPS
- EXP 13.93
- ROIV N/A
- Revenue
- EXP $2,267,040,000.00
- ROIV $122,585,000.00
- Revenue This Year
- EXP $1.49
- ROIV N/A
- Revenue Next Year
- EXP $4.58
- ROIV N/A
- P/E Ratio
- EXP $17.20
- ROIV N/A
- Revenue Growth
- EXP 0.64
- ROIV 140.04
- 52 Week Low
- EXP $201.61
- ROIV $8.73
- 52 Week High
- EXP $321.93
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- EXP 61.02
- ROIV 50.06
- Support Level
- EXP $231.79
- ROIV $10.58
- Resistance Level
- EXP $241.89
- ROIV $11.77
- Average True Range (ATR)
- EXP 6.48
- ROIV 0.34
- MACD
- EXP 1.20
- ROIV -0.07
- Stochastic Oscillator
- EXP 92.51
- ROIV 17.65
About EXP Eagle Materials Inc
Eagle Materials Inc produces and sells construction products and building materials. Construction products include cement, slag, concrete, and aggregates and building materials include cement and gypsum wallboard, and are sold to the construction and building industries. The firm organizes itself into two sectors: Heavy Materials, which includes the Cement and Concrete and Aggregates segments, and Light Materials, which includes the Gypsum Wallboard and Recycled Paperboard segments.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.